Background: There have been no well-documented reports detailing the relationship between skeletal metastasis and tumor markers in a large series of patients. The purpose of our study was to assess the relationship between the clinical features of skeletal metastasis and serum tumor markers and to determine whether tumor markers are a useful modality in the differential diagnosis of skeletal metastasis. Methods: We retrospectively reviewed consecutive 458 patients with skeletal metastasis and divided the patients into two groups according to six clinical presenting factors. We assessed whether these groups influenced the level of the tumor markers in univariate and multivariate analysis. Results: Patients with skeletal metastasis of carcinoma had a higher level of markers CEA (P < 0.0001) and CA19-9 (P = 0.0008) than patients with primary bone tumors and hematological malignancies. Univariate analysis of clinical variables revealed that metastasis on axial skeleton, multiple skeletal metastases and visceral metastasis were associated with the serum CEA and CA19-9 levels. By multivariate analysis, metastasis on axial skeleton, multiple skeletal metastases and visceral metastasis were found to be associated with the serum CEA and CA19-9 levels. At least one of the tumor markers was elevated in 73% of all patients. Conclusions: The higher tumor marker level (CEA, CA19-9) is predictive of metastasis on the axial skeleton, multiple skeletal metastases and visceral metastasis. Tumor markers are useful as a screening test to distinguish skeletal metastases of carcinoma from primary bone tumors or hematological malignancy from primary bone tumor and hematological malignancy.
INTRODUCTION
Skeletal metastasis is the most common of all bone neoplasms. In patients older than 50 years with painful, osteolytic and poorly marginated skeletal lesions, the most frequent diagnosis is skeletal metastasis. Skeletal metastases are reportedly the first manifestation of malignancy in 5-20% of patients with cancer of unknown origin (1) (2) (3) (4) (5) . The primary site at the time of presentation is unknown in 30% of patients with skeletal metastases (6) .
However, these skeletal lesions often include primary bone tumor or hematological malignancies. It is often difficult to distinguish skeletal metastasis of carcinoma from primary bone tumor and hematological malignancy with the imaging studies alone. Serum tumor markers may be useful in differentiating skeletal metastasis of carcinoma from primary bone tumor and hematological malignancy. In recent years, various tumor markers have been established as indicators of the presence of tumors and their volume (7) (8) (9) (10) (11) (12) (13) . However, there have been no well-documented reports detailing the relationship between skeletal metastasis and tumor markers in a large series of patients.
The purpose of our study was to assess the relationship between the clinical features of skeletal metastasis and serum tumor markers and to determine whether tumor markers are a useful modality in the differential diagnosis of skeletal metastasis of carcinoma.
PATIENTS AND METHODS
We retrospectively reviewed consecutive 458 patients who underwent surgical or non-surgical treatment for skeletal metastasis from July 1992 to December 2002 at Nagoya Memorial Hospital and Nagoya University Hospital, Nagoya, Japan. Patients were prospectively identified and registered during that period. There were 258 men and 200 women, with a mean age at the time of diagnosis of 61.1 years (range 28-89 years). The lesions came from a variety of primary sites (Table 1) . The diagnoses were made by independent radiologists and pathologists. The primary bone tumors were five osteosarcomas, five malignant fibrous histiocytomas, three liposarcomas, clear cell sarcoma and angiosarcoma. Multiple myeloma lesions were considered as skeletal metastases, consistent with other studies reporting skeletal metastasis (14) (15) (16) (17) (18) . However, solitary plasmacytoma was excluded from our study. Similarly, malignant lymphoma of bone that did not have an extraosseous lesion was also excluded, but patients with primary lymph node lesion and secondary bone metastasis were included. The primary cancer could not be found in 14 patients despite thorough investigation. Of the 14 patients with undetermined primary cancer, a skeletal biopsy was performed in 10 patients, and the lesion was identified as adenocarcinoma in 9 patients and squamous cell carcinoma in 1 patient. Of 458 patients, 257 (56%) had a history of cancer, and the bone tumor appeared as a metastasis during follow-up. In 201 patients (44%) skeletal metastasis was the first manifestation of malignancy.
The health insurance system in our region allows tests of up to three types of tumor markers in 1 month. Therefore, at initial examinations for skeletal metastasis we selected two or three tumor markers to test for from among the following: serum CEA (carcinoembryonic antigen), CA19-9 (carbohydrate antigen 19-9), CA125 (cancer antigen 125), AFP (alpha-fetoprotein), PSA (prostate-specific antigen), CA15-3 (carbohydrate antigen and SCC (squamous cell carcinoma antigen). We measured AFP in patients with liver dysfunction in which hepatocellular carcinoma was suspected, CA125 in women with a history of gynecological cancer or with gynecological symptoms, SCC in patients who were suspected to have squamous cell carcinoma from lung images and PSA in men with osteosclerotic lesions. The final choice of tumor markers to test for was made by the doctor in charge of each patient. Measurements were made by chemiluminescent enzyme immunoassay. All patients gave their informed consent for every examination.
Carcinoembryonic antigen was measured in 342 patients, CA19-9 in 276 patients, AFP in 152 patients, CA125 in 116 patients, SCC in 44 patients, PSA in 30 patients and CA15-3 in 15 patients. Cut-off values for the respective tumor markers were as follows: CEA, 5 ng/ml; CA19-9, 37 U/ml; AFP, 20 ng/ml; CA125, 35 U/ml; SCC, 1.5 ng/ml; PSA, 4 ng/ml; and CA15-3, 30 U/ml.
We analyzed the abnormal elevation rate beyond the cut-off value of each tumor marker. We divided the patients into two groups according to the six factors described below and assessed whether these groupings influenced the level of the tumor markers in univariate and multivariate analysis.
Twelve potentially prognostic factors, including the condition of the primary lesion, disease-free interval from primary cancer to development of skeletal metastasis, the site of skeletal metastases, pathological fracture, metastatic load and visceral or brain metastasis, were investigated. Each of these six potentially significant factors was grouped in two categories for statistical analysis ( Table 2) .
Condition of the primary lesion was divided into two categories (i) the primary lesion was cured and (ii) the primary lesion was untreated or recurrent. Disease-free interval from primary cancer to development of skeletal metastasis was divided into two categories: (i) patients with no disease-free interval in which skeletal metastasis was the first manifestation of malignancy or found concurrently with the primary lesion and (ii) patients with a disease-free interval in which skeletal metastasis developed after treatment of the primary lesion. Visceral or brain metastases were grouped into two categories: (i) no visceral or brain metastasis and (ii) any visceral or brain metastasis detectable with imaging study. Sites of skeletal metastases were divided into two categories: (i) limited to appendicular bone and (ii) axial bone affected. Metastatic load was subdivided into (i) solitary and (ii) multiple skeletal metastases. Pathological fractures were also divided into (i) with apparent fracture of spine or extremity and (ii) without apparent fracture.
The SPSS 11.0 program for Windows was used for statistical analysis. Univariate analysis was performed with the t-test for categorical variables. Multivariate analysis was performed with multiple linear regression to assess the relationship between clinical features of skeletal metastasis and serum tumor markers. Differences were considered to be statistically significant at P < 0.05. 
RESULTS

ABNORMAL ELEVATION OF EACH TUMOR MARKER
CEA was abnormally elevated in 166 out of 342 (49%) patients: lung 64%, breast 52%, prostate 35%, stomach 48%, liver 17%, colon 80%, multiple myeloma 0%, malignant lymphoma 15%, kidney 0%, 5 of primary unknown 50%, solid carcinoma 51% and hematological malignancies 12%. CA19-9 was abnormally elevated in 78 out of 276 (28%) patients: lung 34%, breast 20%, prostate 21%, stomach 36%, liver 35%, colon 37%, multiple myeloma 0%, malignant lymphoma 0%, kidney 13%, primary unknown 20%, solid carcinoma 30% and hematological malignancies 0%. AFP was abnormally elevated in 29 out of 152 (19%) patients: lung 0%, breast 6%, prostate 0%, stomach 11%, liver 81%, solid carcinoma except liver 6% and hematological malignancies 0%. CA125 was abnormally elevated in 37 out of 116 (32%) patients: lung 63%, breast 27%, stomach 60%, solid carcinoma 38% and 7% (1/14) in hematological malignancies (Table 3) . PSA was measured in 30 out of 35 patients with prostate carcinoma and was abnormally elevated in 27 patients (90%). At least one of the tumor markers of CEA, CA19-9, CA15-3, CA125 and PSA was elevated in 73% of all 458 cases, 76% of the patients with solid carcinoma, 0% of the patients with sarcoma and 9% of the patients with hematological malignancies.
The serum levels of CEA were elevated in 51% of the patients with carcinoma but in 12% of the patients with hematological malignancy and in 0% of the patients with primary bone tumor. The median of the serum CEA levels of the patients with carcinoma was 840.8 ng/ml. The median of the serum CEA levels of the patients with primary bone tumor and hematological malignancy was 1.9 ng/ml. The serum levels of CA19-9 were elevated in 30% of the patients with carcinoma but in 0% of the patients with hematological malignancy and in 0% of the patients with primary bone tumor. The median of the serum CA19-9 levels of the patients with carcinoma was 2314.4 U/ml. The median of the serum CA19-9 levels of the patients with primary bone tumor and hematological malignancy was 86.6 U/ml. Patients with skeletal metastasis of carcinoma had a higher (P < 0.0001) level of marker CEA than patients with primary bone tumors and hematological malignancies; sensitivity 51%, specificity 91%. Patients with skeletal metastasis of carcinoma had a higher (P = 0.0008) level of marker CA19-9 than patients with primary bone tumors and hematological malignancies; sensitivity 30%, specificity 100% (Fig. 1) .
Patients with metastasis on the axial skeleton had a higher (P < 0.0001) level of marker CEA than patients without metastasis on axial skeleton. Patients with metastasis on the axial skeleton had a higher (P = 0.004) level of marker CA19-9 than patients without metastasis on axial skeleton. Patients with multiple metastases had a higher (P = 0.002) level of marker CEA than patients with solitary metastasis. Patients with multiple metastases had a higher (P = 0.005) level of marker CA19-9 than patients with solitary metastasis. Patients with visceral metastasis had a higher (P < 0.0001) level of marker CEA than patients without visceral metastasis. Patients with visceral metastasis had a higher (P < 0.0001) level of marker CA19-9 than patients without visceral metastasis (Table 4) . At least one of the tumor markers of CEA, CA19-9, CA15-3, CA125 and PSA was elevated in 43% of patients with solitary metastasis or without metastasis on axial skeleton.
Univariate analysis of clinical variables revealed that metastasis on axial skeleton, multiple skeletal metastases and visceral metastasis were associated with the serum CEA and CA19-9 levels. By multivariate analysis, metastasis on axial skeleton, multiple skeletal metastases and visceral metastasis were found to be associated with the serum CEA and CA19-9 levels.
DISCUSSION
In patients older than 50 years with osteolytic and poorly marginated skeletal lesions, the most frequent diagnosis is skeletal metastasis of carcinoma. However, these skeletal lesions often include primary bone tumors or hematological malignancies. In skeletal metastasis of carcinoma, main treatment is palliative therapy including radiotherapy, chemotherapy and surgery to maintain quality of life. On the other hand, in primary bone tumor or hematological malignancy radical surgery and intensive chemotherapy are required. In our series, 44% of patients presented without a known primary site and 30% of patients presented with solitary bone lesions. It is sometimes difficult to distinguish skeletal metastasis of carcinoma from a primary bone tumor or hematological malignancy in these patients with the imaging studies alone including plain radiography, computed tomography (CT), Charts show that the levels of CEA and CA19-9 were significantly higher in patients with skeletal metastasis of carcinoma than patients with primary bone tumors and hematological malignancies (CEA, P < 0.0001; CA19-9, P = 0.0008); dashed line: upper limit of the marker; continuous line: median of the marker.
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Tumor markers in skeletal metastasis skeletal metastasis of carcinomas had a higher (P = 0.0008) level of marker CA19-9 than patients with primary bone tumors and hematological malignancies. In patients suspected to have skeletal metastasis, measurement of tumor markers can be useful as a screening test to distinguish skeletal metastasis of carcinoma from primary bone tumor or hematological malignancy.
The abnormal elevation rate of tumor markers varies greatly depending on the cancer stage. It is reported that CEA is elevated in about 20% of patients with lung, breast and colon carcinomas without metastasis (19) (20) (21) (22) . In present study it showed an especially high abnormal elevation rate with lung carcinoma (64%), breast carcinoma (52%) and colon carcinoma (80%). Our study included only patients with skeletal metastases, but the abnormal elevation rates of CEA and CA19-9 were higher than primary carcinomas without metastasis and almost the same as advanced cancers (23) (24) (25) (26) (27) . There are only a few reports about the relation between skeletal metastasis and tumor marker. Shinozaki et al. reported that the tumor marker abnormal elevation rates were 34.6% for CEA, 30.8% for CA19-9 and 30.8% for CA125 in cases of skeletal metastasis (n = 26) (28) . Despite the small number of patients in their report, the results were nearly the same as those from our analysis of a large series of patients. At least one of the tumor markers of CEA, CA19-9, CA15-3, CA125 and PSA was elevated in 73% of all 458 patients. When a cancer metastasis appears in bone, the cancer has metastasized hematogenously and abnormal elevation rate of tumor markers is so high that it is very useful as a screening test.
It is reported that AFP is elevated in 90% of patients with hepatocellular carcinoma (29) . In our study, the abnormal elevation rate was only 14%, but a high rate of 81% (17 of 21 patients) was seen in patients with hepatocellular carcinoma. Prostate-specific antigen was measured in 28 of 35 patients with prostate carcinoma, and a high specificity of 89% (25 of 28 patients) was seen. When an initial diagnosis is skeletal metastasis of unknown primary cancer, use of organ-specific tumor markers such as PSA and AFP is beneficial in determining primary lesions of prostate and hepatocellular carcinoma. Other tumor markers with lower organ specificity are not particularly helpful in identifying the primary site but are useful in differential diagnosis.
Tumor markers showed a lower abnormal elevation rate with renal cell carcinoma (CEA, 0%; CA 19-9, 13%) and thyroid carcinoma (CEA, 0%; CA19-9, 20%) than with other carcinomas in our study. Therefore, if all tumor marker levels are normal, primary bone tumor, hematological malignancy, renal cell carcinoma and thyroid carcinoma would be suspected rather than metastases from other carcinomas such as lung or colorectal carcinoma. Reportedly PET and PET-CT are helpful to determine the primary site in a bone metastasis patient with unknown origin (30) . Unless the initial examinations such as serum tumor markers, chest CT and abdominal CT are able to detect the primary site, we recommend performing PET and PET-CT examination.
By multivariate analysis, metastasis on axial skeleton, multiple skeletal metastases and visceral metastasis were found to be associated with the serum CEA and CA19-9 levels. However, there was no difference associated with the presence of primary lesions, pathological fracture or previous cancer history. The higher tumor marker level (CEA, CA19-9) is predictive of metastasis on the axial skeleton, multiple skeletal metastases and visceral metastasis.
Carcinomas of the lung, breast and prostate are malignant tumors that frequently develop skeletal metastases. In advanced cases skeletal metastases occur in 69% of breast carcinomas (31), 33-85% of prostate carcinomas, 24-55% of lung carcinomas and 35% of renal cell carcinomas (32) . In these patients, evaluation for the development of skeletal metastasis with bone scan is necessary during the follow-up. However, the high expense of bone scan makes it difficult to perform repeatedly. When the tumor marker is elevating, one should suspect that skeletal metastasis is appeared or progressed. Several bone metabolic markers, bone resorption and bone formation markers, are available in recent years, and these markers are reported to be useful to diagnose and monitor the clinical course (33) . In future work we would like to determine these bone metabolic markers in addition to tumor markers. Measuring these markers during follow-up is important as they are indicators for the timing of imaging studies for skeletal metastasis and may give a chance to detect skeletal metastases in its early stage. In patients suspected to have skeletal metastasis, tumor markers should be measured in the initial examination. This will shorten the time required for a definite diagnosis of skeletal metastasis; will be helpful in searching for the primary lesion; and will reduce unnecessary, painful and expensive examinations.
